Fig. 4: Single-organoid analysis reveals the ex vivo intra-tumoral response heterogeneity.

a Bar plot representation of the progression-free survival (PFS) in months per patient. b NDR results upon treatment with gemcitabine-paclitaxel highlighting the 3 distinct responses. Error bars indicate the standard deviation. c Representative brightfield/fluorescence (Cytotox Green) images of PDAC052, PDAC060 and PDAC082 indicating the presence of persistent PDAC organoid clones (black circle). One representative image was selected for visualization out of the two technical replicates. Scale bar=100 µm d Single organoid dose response based on cell death (green area/brightfield area) labeled as fraction affected and area (brightfield) of PDAC052, PDAC060 and PDAC082 treated with gemcitabine-paclitaxel (400 nM:80 nM). Dark grey region (Fraction affected <0.15) indicates resistant, middle grey region sensitive (Fraction affected 0.15-0.34) and light grey highly sensitive (Fraction affected >0.34) PDAC organoid clones. Bubble size correlates with the organoid area. e Relative fraction of resistant, sensitive and highly sensitive PDAC organoids for each patient treated with gemcitabine-paclitaxel (400 nM:80 nM). f Dynamic quantification of single-organoid responses treated with gemcitabine-paclitaxel (400 nM:80 nM) or FOLFIRINOX (20 µM 5-FU:0.0625 µM SN38:2.5 µM Oxaliplatin). The single organoid data was combined from 2 technical replicates.